Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature

摘要: Cystic fibrosis patients suffer increased sputum production and a notable decline in respiratory function throughout the progression of their disease. Patients are left vulnerable to colonization/infection from number pathogens, including Pseudomonas aeruginosa. At present, only antibiotic formulation that is FDA approved for aerosolized delivery tobramycin solution inhalation (TSI). TSI allows targeted lungs indicated maintenance therapy cystic infected with P. Studies demonstrate cyclical treatment associated an increase decrease density patients. Additional benefits include fewer hospitalizations decreased need systemic antibiotics. However, because chronic administration, issues such as emergence resistant organisms toxicity potential concern have also been evaluated. This review details pharmacology literature involving its use